 Christina Finlayson
Concepts (201)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 26 | 2017 | 2139 | 1.020 |
Why?
| | Carcinoma, Ductal, Breast | 5 | 2017 | 82 | 0.500 |
Why?
| | Mastectomy, Segmental | 5 | 2017 | 85 | 0.400 |
Why?
| | Receptors, Estrogen | 7 | 2012 | 429 | 0.340 |
Why?
| | Sentinel Lymph Node Biopsy | 3 | 2008 | 109 | 0.310 |
Why?
| | Lymph Nodes | 3 | 2007 | 469 | 0.310 |
Why?
| | Thoracic Vertebrae | 1 | 2007 | 73 | 0.280 |
Why?
| | Mammography | 1 | 2007 | 139 | 0.260 |
Why?
| | Prostheses and Implants | 1 | 2007 | 141 | 0.260 |
Why?
| | Receptors, Progesterone | 4 | 2012 | 345 | 0.220 |
Why?
| | src Homology Domains | 1 | 2003 | 38 | 0.220 |
Why?
| | Receptor, ErbB-2 | 3 | 2012 | 337 | 0.220 |
Why?
| | Mastectomy | 3 | 2007 | 130 | 0.210 |
Why?
| | Preoperative Care | 2 | 2001 | 343 | 0.200 |
Why?
| | Estrogens | 3 | 2012 | 355 | 0.200 |
Why?
| | Patients | 1 | 2001 | 168 | 0.170 |
Why?
| | Mammaplasty | 1 | 2001 | 97 | 0.170 |
Why?
| | Vitamin E | 1 | 2000 | 118 | 0.170 |
Why?
| | Phytotherapy | 1 | 2000 | 76 | 0.170 |
Why?
| | Postoperative Hemorrhage | 1 | 2000 | 86 | 0.160 |
Why?
| | Neoplasm Staging | 8 | 2010 | 1294 | 0.150 |
Why?
| | Counseling | 1 | 2001 | 386 | 0.150 |
Why?
| | Reoperation | 2 | 2017 | 558 | 0.150 |
Why?
| | Tamoxifen | 5 | 2012 | 199 | 0.150 |
Why?
| | Neoplasms, Radiation-Induced | 1 | 2016 | 71 | 0.130 |
Why?
| | Pelvic Exenteration | 1 | 1996 | 11 | 0.130 |
Why?
| | Pelvic Neoplasms | 1 | 1996 | 19 | 0.130 |
Why?
| | Neoadjuvant Therapy | 3 | 2010 | 387 | 0.130 |
Why?
| | Carcinoma, Lobular | 2 | 2017 | 48 | 0.120 |
Why?
| | Neoplasms, Second Primary | 1 | 2016 | 109 | 0.120 |
Why?
| | Hodgkin Disease | 1 | 2016 | 136 | 0.120 |
Why?
| | Risk Reduction Behavior | 1 | 2016 | 212 | 0.120 |
Why?
| | Antineoplastic Agents, Hormonal | 4 | 2012 | 158 | 0.120 |
Why?
| | Gene Expression Regulation, Neoplastic | 3 | 2010 | 1341 | 0.110 |
Why?
| | Insulin | 1 | 2003 | 2322 | 0.100 |
Why?
| | Signal Transduction | 3 | 2012 | 4930 | 0.100 |
Why?
| | Neoplasms, Hormone-Dependent | 1 | 2012 | 38 | 0.100 |
Why?
| | Practice Patterns, Physicians' | 2 | 2017 | 1294 | 0.100 |
Why?
| | Radiotherapy, Adjuvant | 3 | 2008 | 213 | 0.100 |
Why?
| | Female | 23 | 2017 | 68842 | 0.090 |
Why?
| | Breast | 2 | 2003 | 152 | 0.090 |
Why?
| | Carcinoma in Situ | 1 | 2011 | 45 | 0.090 |
Why?
| | Axilla | 2 | 2007 | 43 | 0.090 |
Why?
| | Practice Guidelines as Topic | 2 | 2017 | 1537 | 0.090 |
Why?
| | Keratin-5 | 1 | 2010 | 49 | 0.090 |
Why?
| | Radiotherapy | 2 | 2008 | 186 | 0.090 |
Why?
| | Middle Aged | 14 | 2017 | 31322 | 0.080 |
Why?
| | Palliative Care | 1 | 1996 | 718 | 0.080 |
Why?
| | BRCA2 Protein | 1 | 2009 | 53 | 0.080 |
Why?
| | Estrogen Receptor alpha | 1 | 2010 | 135 | 0.080 |
Why?
| | Thrombophilia | 1 | 2009 | 68 | 0.080 |
Why?
| | Humans | 30 | 2017 | 130305 | 0.080 |
Why?
| | Pregnancy Complications, Neoplastic | 1 | 2009 | 52 | 0.080 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2010 | 755 | 0.070 |
Why?
| | Aromatase Inhibitors | 1 | 2008 | 52 | 0.070 |
Why?
| | Adjuvants, Immunologic | 1 | 2008 | 220 | 0.070 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 1 | 2007 | 124 | 0.070 |
Why?
| | Breast Cyst | 1 | 2006 | 2 | 0.070 |
Why?
| | Cyst Fluid | 1 | 2006 | 27 | 0.070 |
Why?
| | Carcinoma, Papillary | 1 | 2007 | 77 | 0.070 |
Why?
| | Sternum | 1 | 2006 | 25 | 0.070 |
Why?
| | Biomarkers, Tumor | 2 | 2010 | 1196 | 0.060 |
Why?
| | Melatonin | 1 | 2006 | 121 | 0.060 |
Why?
| | Phosphoproteins | 2 | 2008 | 333 | 0.060 |
Why?
| | Carcinoma, Ductal | 1 | 2005 | 11 | 0.060 |
Why?
| | Adult | 12 | 2017 | 35711 | 0.060 |
Why?
| | Ki-67 Antigen | 1 | 2005 | 109 | 0.060 |
Why?
| | Enzyme Inhibitors | 1 | 2008 | 832 | 0.060 |
Why?
| | Combined Modality Therapy | 4 | 2008 | 1219 | 0.060 |
Why?
| | Retroviridae Proteins, Oncogenic | 1 | 2003 | 11 | 0.060 |
Why?
| | Oncogene Protein v-akt | 1 | 2003 | 26 | 0.060 |
Why?
| | Liver Neoplasms | 1 | 2009 | 643 | 0.060 |
Why?
| | Insulin Receptor Substrate Proteins | 1 | 2003 | 59 | 0.050 |
Why?
| | Bone Neoplasms | 1 | 2006 | 228 | 0.050 |
Why?
| | Receptor, Insulin | 1 | 2003 | 100 | 0.050 |
Why?
| | rhoA GTP-Binding Protein | 1 | 2003 | 91 | 0.050 |
Why?
| | Retrospective Studies | 5 | 2017 | 14675 | 0.050 |
Why?
| | Multiple Sclerosis | 1 | 2008 | 436 | 0.050 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2005 | 533 | 0.050 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2003 | 265 | 0.050 |
Why?
| | Urachus | 1 | 2002 | 1 | 0.050 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2003 | 316 | 0.050 |
Why?
| | Referral and Consultation | 1 | 2007 | 736 | 0.050 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2007 | 959 | 0.050 |
Why?
| | Aged | 6 | 2017 | 22282 | 0.050 |
Why?
| | Prospective Studies | 2 | 2003 | 7131 | 0.040 |
Why?
| | Mastectomy, Radical | 1 | 2000 | 2 | 0.040 |
Why?
| | Nurse Anesthetists | 1 | 2000 | 3 | 0.040 |
Why?
| | Tomography, X-Ray Computed | 2 | 2007 | 2551 | 0.040 |
Why?
| | Phosphorylation | 1 | 2003 | 1709 | 0.040 |
Why?
| | Gynecomastia | 1 | 1998 | 6 | 0.040 |
Why?
| | Urinary Bladder Neoplasms | 1 | 2002 | 227 | 0.040 |
Why?
| | Cluster Analysis | 2 | 2012 | 485 | 0.040 |
Why?
| | Immunohistochemistry | 3 | 2008 | 1711 | 0.040 |
Why?
| | Endocrine System Diseases | 1 | 1998 | 32 | 0.040 |
Why?
| | Blood Coagulation | 1 | 2000 | 234 | 0.040 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2012 | 773 | 0.040 |
Why?
| | Survival Rate | 2 | 2008 | 1904 | 0.040 |
Why?
| | Margins of Excision | 1 | 2017 | 38 | 0.040 |
Why?
| | Apoptosis | 2 | 2010 | 2519 | 0.030 |
Why?
| | Gene Expression Profiling | 3 | 2008 | 1714 | 0.030 |
Why?
| | Ultrasonography | 1 | 2000 | 731 | 0.030 |
Why?
| | Aged, 80 and over | 2 | 2010 | 7128 | 0.030 |
Why?
| | Estradiol | 2 | 2010 | 498 | 0.030 |
Why?
| | Quality Indicators, Health Care | 1 | 2017 | 301 | 0.030 |
Why?
| | Decision Making | 1 | 2001 | 842 | 0.030 |
Why?
| | Consensus | 1 | 2017 | 652 | 0.030 |
Why?
| | Lymph Node Excision | 2 | 2009 | 168 | 0.030 |
Why?
| | Guideline Adherence | 1 | 2017 | 534 | 0.030 |
Why?
| | Adenocarcinoma | 1 | 2000 | 916 | 0.030 |
Why?
| | CD24 Antigen | 1 | 2012 | 20 | 0.030 |
Why?
| | Breast Neoplasms, Male | 1 | 2012 | 29 | 0.020 |
Why?
| | Patient Selection | 1 | 1996 | 678 | 0.020 |
Why?
| | Hyaluronan Receptors | 1 | 2012 | 96 | 0.020 |
Why?
| | Mice, SCID | 1 | 2012 | 349 | 0.020 |
Why?
| | Tumor Burden | 1 | 2012 | 285 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 1996 | 1015 | 0.020 |
Why?
| | Mass Screening | 1 | 1998 | 1139 | 0.020 |
Why?
| | Cell Line, Tumor | 2 | 2010 | 3185 | 0.020 |
Why?
| | Colorado | 2 | 2017 | 4471 | 0.020 |
Why?
| | Biopsy, Needle | 1 | 2011 | 192 | 0.020 |
Why?
| | Mice, Inbred NOD | 1 | 2012 | 586 | 0.020 |
Why?
| | Tumor Cells, Cultured | 1 | 2012 | 937 | 0.020 |
Why?
| | Gene Regulatory Networks | 1 | 2012 | 283 | 0.020 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 1 | 2010 | 96 | 0.020 |
Why?
| | Prognosis | 2 | 2009 | 3830 | 0.020 |
Why?
| | Peptide Mapping | 1 | 2010 | 62 | 0.020 |
Why?
| | Databases, Protein | 1 | 2010 | 61 | 0.020 |
Why?
| | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2010 | 136 | 0.020 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2012 | 815 | 0.020 |
Why?
| | Pregnancy Trimester, Second | 1 | 2009 | 76 | 0.020 |
Why?
| | Observer Variation | 1 | 2010 | 324 | 0.020 |
Why?
| | Interferon beta-1a | 1 | 2008 | 12 | 0.020 |
Why?
| | Cyclophosphamide | 1 | 2009 | 232 | 0.020 |
Why?
| | Pregnancy Trimester, First | 1 | 2009 | 135 | 0.020 |
Why?
| | Glatiramer Acetate | 1 | 2008 | 18 | 0.020 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2009 | 183 | 0.020 |
Why?
| | Databases as Topic | 1 | 2008 | 65 | 0.020 |
Why?
| | Perilipin-1 | 1 | 2008 | 16 | 0.020 |
Why?
| | Estrogen Receptor Modulators | 1 | 2008 | 17 | 0.020 |
Why?
| | Interferon-beta | 1 | 2008 | 88 | 0.020 |
Why?
| | Neoplasm Invasiveness | 1 | 2010 | 484 | 0.020 |
Why?
| | Neoplastic Stem Cells | 1 | 2012 | 387 | 0.020 |
Why?
| | S100 Proteins | 1 | 2008 | 40 | 0.020 |
Why?
| | Perimenopause | 1 | 2008 | 63 | 0.020 |
Why?
| | Androstadienes | 1 | 2008 | 107 | 0.020 |
Why?
| | Doxorubicin | 1 | 2009 | 321 | 0.020 |
Why?
| | Mastectomy, Modified Radical | 1 | 2007 | 6 | 0.020 |
Why?
| | SEER Program | 1 | 2008 | 208 | 0.020 |
Why?
| | Lymphatic Metastasis | 1 | 2008 | 319 | 0.020 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2008 | 323 | 0.020 |
Why?
| | Selective Estrogen Receptor Modulators | 1 | 2007 | 26 | 0.020 |
Why?
| | Blotting, Western | 1 | 2010 | 1201 | 0.020 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 1 | 2007 | 54 | 0.020 |
Why?
| | Dehydroepiandrosterone Sulfate | 1 | 2006 | 46 | 0.020 |
Why?
| | Mice, Nude | 1 | 2008 | 688 | 0.020 |
Why?
| | Epidermal Growth Factor | 1 | 2006 | 171 | 0.020 |
Why?
| | Transcriptome | 1 | 2012 | 890 | 0.020 |
Why?
| | Neoplasms | 1 | 2000 | 2467 | 0.020 |
Why?
| | Positron-Emission Tomography | 1 | 2006 | 285 | 0.010 |
Why?
| | Neoplasm Proteins | 1 | 2007 | 430 | 0.010 |
Why?
| | Quality of Life | 1 | 1996 | 2735 | 0.010 |
Why?
| | Patient Care Planning | 1 | 2005 | 152 | 0.010 |
Why?
| | Transforming Growth Factor beta | 1 | 2006 | 465 | 0.010 |
Why?
| | Carrier Proteins | 1 | 2008 | 738 | 0.010 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2005 | 383 | 0.010 |
Why?
| | Mice | 2 | 2012 | 16832 | 0.010 |
Why?
| | Proteomics | 1 | 2010 | 1008 | 0.010 |
Why?
| | Antineoplastic Agents | 2 | 2008 | 2078 | 0.010 |
Why?
| | Peptides | 1 | 2008 | 917 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2017 | 10341 | 0.010 |
Why?
| | Diagnosis, Differential | 1 | 2007 | 1442 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2010 | 2381 | 0.010 |
Why?
| | Postmenopause | 1 | 2005 | 370 | 0.010 |
Why?
| | Umbilicus | 1 | 2002 | 16 | 0.010 |
Why?
| | Abdominal Neoplasms | 1 | 2002 | 32 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2010 | 3069 | 0.010 |
Why?
| | Phenotype | 1 | 2010 | 3084 | 0.010 |
Why?
| | Biopsy | 1 | 2005 | 1107 | 0.010 |
Why?
| | Age Factors | 1 | 2008 | 3153 | 0.010 |
Why?
| | Liver | 1 | 2009 | 1846 | 0.010 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2009 | 1579 | 0.010 |
Why?
| | United States | 1 | 2017 | 14110 | 0.010 |
Why?
| | Hospitals, Private | 1 | 1999 | 12 | 0.010 |
Why?
| | Hospitals, County | 1 | 1999 | 10 | 0.010 |
Why?
| | Male | 4 | 2012 | 63748 | 0.010 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 2000 | 163 | 0.010 |
Why?
| | Hospitals, University | 1 | 1999 | 177 | 0.010 |
Why?
| | Leydig Cell Tumor | 1 | 1998 | 7 | 0.010 |
Why?
| | Animals | 2 | 2012 | 35076 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2009 | 5741 | 0.010 |
Why?
| | Testicular Neoplasms | 1 | 1998 | 102 | 0.010 |
Why?
| | Pregnancy | 1 | 2009 | 6301 | 0.010 |
Why?
| | NF-kappa B | 1 | 2000 | 691 | 0.010 |
Why?
| | Cost-Benefit Analysis | 1 | 1998 | 621 | 0.010 |
Why?
| | Socioeconomic Factors | 1 | 1999 | 1200 | 0.010 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2000 | 1210 | 0.010 |
Why?
| | Patient Education as Topic | 1 | 1999 | 739 | 0.010 |
Why?
| | Risk Factors | 1 | 2008 | 9865 | 0.010 |
Why?
| | Models, Biological | 1 | 2000 | 1716 | 0.010 |
Why?
| | Adolescent | 1 | 1998 | 20374 | 0.000 |
Why?
|
|
Finlayson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|